Browsing by author "Price, Timothy J"
Sort by:
Title A-Z
-
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
Price, Timothy J; Bruhn, Maressa A; Lee, Chee K; Hardingham, Jennifer E; Townsend, Amanda R; Mann, Kristy P; Simes, John; Weickhardt, Andrew; Wrin, Joseph W; Wilson, Kate; Gebski, Val; van Hazel, Guy; Robinson, Bridget; Cunningham, David; Tebbutt, Niall CPublished 2015-03-05Background: Mutations affecting RAS genes are now established predictive markers of nonresponse to anti-EGFR antibodies in advanced CRC. This analysis assessed the prognostic and predictive impact of extended RAS and PIK3CA ...Open AccessArticle -
The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study
Carter, Hannah; Zannino, Diana; Simes, R John; Schofield, Deborah J; Howard, Kirsten; Zalcberg, John R; Price, Timothy J; Tebbutt, Niall CPublished 2015-12-14Background: Based on the clinical data, bevacizumab has been approved in Australia and globally for the treatment of advanced colorectal cancer. However, limited evidence exists for its cost-effectiveness. The purpose of ...Open AccessArticle -
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer receiving bevacizumab
Price, Timothy J; Hardingham, Jennifer E; Lee, Chee K; Townsend, Amanda R; Wrin, Joseph W; Wilson, Kate; Weickhardt, Andrew; Simes, Robert J; Murone, Carmel; Tebbutt, Niall CPublished 2013-03-01Loss of phosphatase and tensin homologue (PTEN) expression may be prognostic in colorectal cancer (CRC) and may have a correlation with vascular endothelial growth factor (VEGF) expression via hypoxia-inducible factor 1 ...Open AccessArticle
Sort by:
Title A-Z